These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31661724)

  • 41. Altered probe pressure and body position increase diagnostic accuracy for men and women in detecting hepatic steatosis using quantitative ultrasound.
    Byenfeldt M; Kihlberg J; Nasr P; Grönlund C; Lindam A; Bartholomä WC; Lundberg P; Ekstedt M
    Eur Radiol; 2024 Mar; ():. PubMed ID: 38459346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease.
    Shao CX; Ye J; Dong Z; Li F; Lin Y; Liao B; Feng S; Zhong B
    Ther Adv Chronic Dis; 2021; 12():20406223211033119. PubMed ID: 34408822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.
    Bannas P; Kramer H; Hernando D; Agni R; Cunningham AM; Mandal R; Motosugi U; Sharma SD; Munoz del Rio A; Fernandez L; Reeder SB
    Hepatology; 2015 Nov; 62(5):1444-55. PubMed ID: 26224591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction.
    Satapathy SK; Gonzalez HC; Vanatta J; Dyer A; Angel W; Nouer SS; Kocak M; Kedia SK; Jiang Y; Clark I; Yadak N; Nezakagtoo N; Helmick R; Horton P; Campos L; Agbim U; Maliakkal B; Maluf D; Nair S; Halford HH; Eason JD
    PLoS One; 2020; 15(5):e0232006. PubMed ID: 32407331
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography.
    Kwon EY; Kim YR; Kang DM; Yoon KH; Lee YH
    Clin Imaging; 2021 Aug; 76():53-59. PubMed ID: 33549920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accuracy of Multi-echo Dixon Sequence in Quantification of Hepatic Steatosis.
    Yurdaisik I; Nurili F
    Cureus; 2020 Feb; 12(2):e7103. PubMed ID: 32231898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis.
    Nasr P; Forsgren MF; Ignatova S; Dahlström N; Cedersund G; Leinhard OD; Norén B; Ekstedt M; Lundberg P; Kechagias S
    Gastroenterology; 2017 Jul; 153(1):53-55.e7. PubMed ID: 28286210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
    Suzuki Y; Maekawa S; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Takada H; Muraoka M; Sato M; Takano S; Fukasawa M; Yamaguchi T; Funayama S; Morisaka H; Onishi H; Enomoto N
    J Gastroenterol Hepatol; 2023 Jun; 38(6):921-929. PubMed ID: 36811251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility.
    Kato S; Iwasaki A; Kurita Y; Arimoto J; Yamamoto T; Hasegawa S; Sato T; Imajo K; Hosono K; Kobayashi N; Yoneda M; Higurashi T; Kubota K; Utsunomiya D; Nakajima A
    PLoS One; 2019; 14(12):e0224921. PubMed ID: 31790429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantification of Liver Fat Content With Unenhanced MDCT: Phantom and Clinical Correlation With MRI Proton Density Fat Fraction.
    Pickhardt PJ; Graffy PM; Reeder SB; Hernando D; Li K
    AJR Am J Roentgenol; 2018 Sep; 211(3):W151-W157. PubMed ID: 30016142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
    Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Utility of Ultrasound-Guided Attenuation Parameter for the Detection and Quantification of Hepatic Steatosis in Patients with Fatty Liver Diagnosed by Computed Tomography.
    Iwashita H; Shakado S; Yoshimaru N; Tanaka H; Koto F; Tanaka T; Takata K; Yokoyama K; Yamaguchi M; Irie M; Hirai F
    Ultrasound Med Biol; 2022 Jul; 48(7):1282-1289. PubMed ID: 35397929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Diagnostic Value of Ultrasound-guided Attenuation Parameter (UGAP) in metabolic fatty liver disease.
    Wu H; Zeng Y; Chen F; Peng J; Chen L
    Curr Med Imaging; 2024 Feb; ():. PubMed ID: 38333977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.
    Loomba R; Schork N; Chen CH; Bettencourt R; Bhatt A; Ang B; Nguyen P; Hernandez C; Richards L; Salotti J; Lin S; Seki E; Nelson KE; Sirlin CB; Brenner D;
    Gastroenterology; 2015 Dec; 149(7):1784-93. PubMed ID: 26299412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reliability and stability of ultrasound-guided attenuation parameter in evaluating hepatic steatosis.
    Zhang X; Luo L; Liu H; Liang S; Xu E
    J Ultrasound; 2024 Mar; 27(1):145-152. PubMed ID: 38281291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.
    Schwimmer JB; Middleton MS; Behling C; Newton KP; Awai HI; Paiz MN; Lam J; Hooker JC; Hamilton G; Fontanesi J; Sirlin CB
    Hepatology; 2015 Jun; 61(6):1887-95. PubMed ID: 25529941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.